Biogen Inc. announced that Chief Executive Officer Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller. Vounatsos, who was named as the CEO in 2016, will continue in his role until a successor is appointed.